Statutory
Rules
1974
No. 37
REGULATIONS
UNDER THE NATIONAL HEALTH ACT 1953-1973.*
WHEREAS
it is provided by sub-section 101 (4) of the National Health Act 1953-1973
that a drug or medicinal preparation that was not a pharmaceutical benefit
under the National Health Act 1953-1958 immediately before the
commencement of that sub-section shall not be prescribed as a pharmaceutical
benefit in accordance with section 85 of the National Health Act 1953-1973
unless the Pharmaceutical Benefits Advisory Committee has recommended to the
Minister that it be so prescribed:
AND WHEREAS that Committee has recommended to the
Minister that the following drugs and medicinal preparations be prescribed as
pharmaceutical benefits under section 85 of the National Health Act 1953-1973,
namely the drugs and medicinal preparations specified in the Third Schedule to
the National Health (Pharmaceutical Benefits) Regulations, as amended by the
following Regulations, that had not previously been prescribed as
pharmaceutical benefits:
NOW THEREFORE I, THE GOVERNOR-GENERAL of Australia,
acting with the advice of the Executive Council, hereby make the following
Regulations under the National Health Act 1953-1973.
Dated
this twenty-sixth day of March, 1974.
PAUL
HASLUCK
Governor-General.
By
His Excellency’s Command,
D.
EVERINGHAM
Minister
of State for Health.
amendments
of the national health (pharmaceutical benefits) Regulations
Commencement.
1. These Regulations shall come into
operation on 1 April 1974.
First Schedule.
2. The First Schedule to the
National Health (Pharmaceutical Benefits) Regulations is amended as set out in
Schedule 1.
Second Schedule.
3. The
Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is
amended as set out in Schedule 2.
* Notified in the Australian
Government Gazette on 29 March 1974.
Statutory Rules 1960, No. 17, as amended by
Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34,
101 and 114; 1963, Nos. 34, 69 and 107; 1964, Nos. 12, 57 and 135; 1965, Nos.
51, 151 and 152; 1966, Nos. 80 and 144; 1967, Nos. 67, 116 and 158; 1968, Nos.
44, 76, 88 and 146; 1969, Nos. 44, 107 and 185; 1970, Nos. 39, 94, 119 and 186;
1971, Nos. 44, 101, 136 and 154; 1972, Nos. 32, 121 and 205; and 1973, Nos. 15,
57, 139 and 229.
Third Schedule.
4. The Third Schedule to the
National Health (Pharmaceutical Benefits) Regulations is amended as set out in
Schedule 3.
Fifth Schedule.
5. The Fifth Schedule to the
National Health (Pharmaceutical Benefits) Regulations is amended as set out in
Schedule 4.
SCHEDULE 1 Regulation 2
Amendments of the First Schedule to the National
Health (Pharmaceutical Benefits) Regulations
1. Omit item 40.
|
2. Omit item 136.
|
3. After item 143 insert the following item:—
|
“143a.
Dichloralphenazone Tablets”.
|
4. After item 146 insert the following item:—
|
“146a.
Dicophane”.
|
5. After item 290 insert the following item:—
|
“290aa. Mepacrine Tablets”.
|
6. After item 521 insert the following item:—
|
“521 a.
Triclofos Tablets”.
|
SCHEDULE
2 Regulation
3
Amendments of the Second Schedule to the National
Health (Pharmaceutical Benefits) Regulations
1. After item 26 insert the following item:—
“26a
| Bisacodyl.............................. | Dioctyl Sodium Sulphosuccinate, B.P.C, with Bisacodyl”. |
2. Omit item 50.
|
3. Omit item 54, substitute the following item:—
|
“54
| Demeclocycline Hydrochloride | Nystatin with Demeclocycline
Hydrochloride”. |
4. After item 58 insert the following item:—
|
“58a
| Dextropropoxyphene Hydrochloride | Paracetamol with
Dextropropoxyphene Hydrochloride”. |
5. Omit item 61.
|
6. Omit item 71, substitute the following item:—
|
“71
| Dioctyl Sodium Sulphosuccinate, B.P.C.
| Bisacodyl with Dioctyl Sodium
Sulphosuccinate B.P.C. |
Danthron with Dioctyl Sodium
Sulphosuccinate, B.P.C.”. |
7. Omit item 111.
|
8. Omit from item 151 the words:—
|
“Demethylchlortetracycline with
Nystatin ”(in the third column), substitute the words:—
|
“Demeclocycline with Nystatin”.
|
9. Omit item 202, substitute the following item:—
|
“202
| Sodium Lactate..................... | Potassium Chloride with Magnesium Chloride, Sodium
Chloride and Sodium Lactate
|
Potassium Chloride with Dextrose
and Sodium Lactate”. |
SCHEDULE 3 Regulation 4
Amendments of the Third Schedule to the
National Health (Pharmaceutical Benefits) Regulations
1. Omit item 95.
|
2. Omit item 107.
|
3. Omit item 131.
|
4. Omit item 256.
|
5. After item 339 insert the following item:—
|
“339a. Squill
Oxymel, B.P.C.”.
|
SCHEDULE
4 Regulation
5
Amendments of the Fifth Schedule to the
National Health (Pharmaceutical Benefits) Regulations
1.
Omit item 18.
|
2.
Omit item 48, substitute the following item:—
|
“48
| Cholestyramine.................... | With the
written authority of the Director-General— |
Bile salt malabsorption associated with ileal resection or proven
ileal disease
|
Pruritus associated with partial biliary obstruction not
responding to other therapy
|
Treatment of severe hypercholesterolemia”.
|
3. Omit item 50, substitute the
following item:—
|
“50
| Clofibrate............................ | With the
written authority of the Director-General— |
Diabetic retinopathy (exudative)
|
Initial treatment with clofibrate of hyperlipidaemia
not responding to dietary therapy
|
A second or subsequent course of treatment of hyperlipidaemia
where significant lowering of serum triglyceride or serum cholesterol
subsequent to initial treatment with clofibrate has been established by
laboratory report”.
|
4. Omit item 58.
|
5. Omit item 66, substitute the
following item:—
|
“66
| Dextrose Polymer................ | With the
written authority of the Director-General— |
Phenylketonuria
|
Tube-feeding
of infants with swallowing defects”.
|
6. Omit item 70, substitute the
following item:—
|
“70
| Dihydrotachysterol............... | With the
written authority of the Director-General— |
Hypoparathyroidism
|
Osteomalacia following gastrectomy or severe steatorrhoea
|
Vitamin
D-resistant rickets”.
|
7. Omit item 73, substitute the
following item:—
|
“73
| (1) Dioctyl Sodium Sulphosuccinate | Any disease or condition in a pensioner”. |
(2) Dioctyl Sodium Sulphosuccinate with
Bisacodyl |
(3)DioctylSodiumSulphosuccinatewith
Danthron |
8. Omit items 86 and 87, substitute the
following items:—
|
“86
| (1) Folic Acid, B.P. | Cystic fibrosis |
(2) Folic Acid Tablets, B.P., 5 mg. | Haemolytic anaemia, chronic |
Proven folic
acid deficiency |
Sprue or the
sprue-like syndrome |
87
| Folic Acid Tablets, B.P., 500 µ g. | Cystic fibrosis |
Haemolytic anaemia, chronic Pregnancy”. |
Schedule 4—continued
9. Omit item 109, substitute the following item:—
|
“109
| Influenza Vaccine
| For prophylaxis of— |
children who have attained the age of
one year but have not attained the age of five years pensioners
|
persons suffering from any severe
debilitating disease, chronic heart disease or chronic pulmonary disease”.
|
10. Add at the end of item 131 the words: — |
“Precocious Puberty” (in the third column).
|
11. Omit items 132 and 133, substitute the
following items:— |
“132
| Medroxyprogesterone Acetate Injections,
50 mg. in 1 ml.
| Carcinoma of the breast |
Carcinoma of the endometrium |
Hypernephroma |
Precocious puberty |
133
| Medroxyprogesterone Acetate Injections,
150 mg. in 1 ml.
| Carcinoma of the breast |
Carcinoma of the endometrium |
Hypernephroma |
Precocious puberty”. |
12. Omit item 158, substitute the
following items:—
|
“158
| Norethisterone Acetate, B.P., Tablets,
10 mg. | Carcinoma of the breast |
Carcinoma of the endometrium |
158A
| Norethisterone Acetate, B.P., Tablets,
2.5 mg. | Endometriosis |
Metropathia haemorrhagica |
Precocious puberty |
Turner’s syndrome”. |
13. Omit from item 200 the words:—
|
“(4) Sodium Aminosalicylate
with Isoniazid, B.P.” (in the second column).
|